The collaboration builds on the internal strengths of Bayer in antibody design, synthesis and machine learning, complementing ...
The discovery and optimization of antibodies, whether through traditional methods or with the assistance of artificial intelligence, necessitates rapid and reliable data generation. Here we introduce ...
Antibody production can slow research to a crawl. As senior vice president of Biointron, Lei Shi works with scientists around the globe to optimize and expedite their antibody projects, from start to ...
Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.
The antibody therapeutics industry is growing at an incredible pace. From early monoclonal therapeutic antibodies to modern bispecific and multispecific antibodies, single domain antibodies (VHHs), ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
For decades, antibodies have been one of the crown jewels of modern medicine—powerful molecules that can neutralize viruses, tame autoimmune diseases, and revolutionize cancer care. Yet despite their ...
The oPool + display platform combines technologies to make and test large numbers of antibodies at once. Antibodies are the critical targeting agents of the immune system and the crux of immune ...
The oPool+ display platform combines technologies to make and test large numbers of antibodies at once. Illinois researchers analyzed how antibodies bind to the influenza protein hemagglutinin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results